{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:48:37Z","timestamp":1768513717160,"version":"3.49.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["16-28157A"],"award-info":[{"award-number":["16-28157A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Progres Nr. Q06\/LF1"],"award-info":[{"award-number":["Progres Nr. Q06\/LF1"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["LO1611 (under NPU I program)"],"award-info":[{"award-number":["LO1611 (under NPU I program)"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12954-018-0268-0","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T08:37:22Z","timestamp":1543912642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-5744","authenticated-orcid":false,"given":"Viktor","family":"Mrav\u010d\u00edk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jan\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbora","family":"Drbohlavov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Popov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pirona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"268_CR1","doi-asserted-by":"publisher","DOI":"10.18356\/bdf42380-en","volume-title":"World Drug Report 2014","author":"United Nations Office on Drug and Crime","year":"2014","unstructured":"United Nations Office on Drug and Crime. World Drug Report 2014. New York: United Nations; 2014."},{"key":"268_CR2","volume-title":"Trends and development","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2017. In: Trends and development; 2017."},{"issue":"10","key":"268_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/070674370605101002","volume":"51","author":"B Fischer","year":"2006","unstructured":"Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatr. 2006;51(10):624\u201334.","journal-title":"Can J Psychiatr"},{"key":"268_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874941001205010001","volume":"5","author":"M Donmall","year":"2012","unstructured":"Donmall M, Jones A, Weston S, Davies L, Hayhurst KP, Millar T. The Drug Treatment Outcomes Research Study (DTORS): research design and baseline data. The Open Addiction Journal. 2012;5:1\u201311.","journal-title":"The Open Addiction Journal"},{"key":"268_CR5","doi-asserted-by":"publisher","DOI":"10.1037\/e561952009-001","volume-title":"Dangerousness of drugs a guide to the risks and harms associated with substance misuse","author":"D Best","year":"2003","unstructured":"Best D, Gross S, Vingoe L, Witton J, Strang J. Dangerousness of drugs a guide to the risks and harms associated with substance misuse. London: National Addiction Centre and Department of Health; 2003."},{"issue":"6","key":"268_CR6","first-page":"503","volume":"15","author":"D Hedrich","year":"2008","unstructured":"Hedrich D, Pirona A, Wiessing L. From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe. Drugs: education, prevention and policy. 2008;15(6):503\u201317.","journal-title":"Drugs: education, prevention and policy"},{"key":"268_CR7","doi-asserted-by":"crossref","unstructured":"Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane database of systematic reviews. 2004:CD002207.","DOI":"10.1002\/14651858.CD002207.pub2"},{"issue":"9","key":"268_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392.","journal-title":"Addiction"},{"key":"268_CR9","doi-asserted-by":"crossref","unstructured":"Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. 2008:CD004145.","DOI":"10.1002\/14651858.CD004145.pub3"},{"key":"268_CR10","first-page":"Cd004145","volume-title":"The Cochrane database of systematic reviews","author":"L Gowing","year":"2011","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral Substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. 2011(8):Cd004145."},{"issue":"4","key":"268_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005;28(4):321\u20139.","journal-title":"J Subst Abus Treat"},{"key":"268_CR12","doi-asserted-by":"publisher","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;(10):CD004147. \n                    https:\/\/doi.org\/10.1002\/14651858.CD004147.pub4\n                    \n                  .","DOI":"10.1002\/14651858.CD004147.pub4"},{"key":"268_CR13","doi-asserted-by":"publisher","first-page":"e5945","DOI":"10.1136\/bmj.e5945","volume":"345","author":"GJ MacArthur","year":"2012","unstructured":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.","journal-title":"BMJ"},{"issue":"3","key":"268_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.drugalcdep.2012.02.005","volume":"124","author":"I Havnes","year":"2012","unstructured":"Havnes I, Bukten A, Gossop M, Waal H, Stangeland P, Clausen T. Reductions in convictions for violent crime during opioid maintenance treatment: a longitudinal national cohort study. Drug Alcohol Depend. 2012;124(3):307\u201310.","journal-title":"Drug Alcohol Depend"},{"key":"268_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug & Alcohol Dependence. 2016;161:1\u20138.","journal-title":"Drug & Alcohol Dependence"},{"issue":"6","key":"268_CR16","first-page":"440","volume":"21","author":"Adrian Octavian Abagiu","year":"2014","unstructured":"Abagiu AO, Cavar Z, Dannon P, George P, Habrat B, Mahomedy Z, et al. Outcomes from the International Survey Informing Greater Insights in Opioid Dependence Treatment (INSIGHT) project. Drugs: Education, Prevention, and Policy. 2014;21(6):1\u201311.","journal-title":"Drugs: Education, Prevention and Policy"},{"issue":"8","key":"268_CR17","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55\u201363.","journal-title":"Am J Public Health"},{"issue":"6","key":"268_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/add.13755","volume":"112","author":"MJM Vranken","year":"2017","unstructured":"Vranken MJM, Mantel-Teeuwisse AK, Junger S, Radbruch L, Scholten W, Lisman JA, et al. Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries. Addiction. 2017;112(6):1069\u201376.","journal-title":"Addiction"},{"key":"268_CR19","unstructured":"European Monitoring Centre for Drugs and Drug Addiction Statistical Bulletin 2018 \u2014 Health and Social Responses 2018 [cited 2018 20 Oct]. Available from: \n                    http:\/\/www.emcdda.europa.eu\/data\/stats2018\/hsr\n                    \n                  ."},{"key":"268_CR20","unstructured":"European Monitoring Centre for Drugs and Drug Addiction Perspectives on Drugs Strategies to prevent diversion of opioid substitution treatment medications Lisbon: EMCDDA; 2016. Available from: \n                    http:\/\/www.emcdda.europa.eu\/topics\/pods\/preventing-diversion-of-opioid-substitution-treatment_en\n                    \n                  ."},{"issue":"6","key":"268_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s11524-012-9691-9","volume":"89","author":"SE Lankenau","year":"2012","unstructured":"Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Patterns of prescription drug misuse among young injection drug users. J Urban Health. 2012;89(6):1004\u201316.","journal-title":"J Urban Health"},{"issue":"1","key":"268_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/10550887.2012.759860","volume":"32","author":"RT Furst","year":"2013","unstructured":"Furst RT. Suboxone misuse along the opiate maintenance treatment pathway. J Addict Dis. 2013;32(1):53\u201367.","journal-title":"J Addict Dis"},{"issue":"6","key":"268_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000448616","volume":"22","author":"M Bleckwenn","year":"2016","unstructured":"Bleckwenn M, Heister L, Weckbecker M, Weckbecker K, Mucke M. Misuse of substitution drugs in the substitution-based therapy. Eur Addict Res. 2016;22(6):322\u20138.","journal-title":"Eur Addict Res"},{"issue":"6","key":"268_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/ADM.0000000000000436","volume":"12","author":"Jennifer J. Carroll","year":"2018","unstructured":"Carroll JJ, Rich JD, Green TC. The more things change: buprenorphine\/naloxone diversion continues while treatment remains inaccessible. J Addict Med. 2018;12(6):459\u201365. \n                    https:\/\/doi.org\/10.1097\/ADM.0000000000000436\n                    \n                  .","journal-title":"Journal of Addiction Medicine"},{"key":"268_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/978-88-470-5322-9_26","volume-title":"Textbook of addiction treatment: international perspectives","author":"H Alho","year":"2015","unstructured":"Alho H. Opioid agonist diversion in opioid-dependence treatment. In: el-Guebaly N, Carr\u00e0 G, Galanter M, editors. Textbook of addiction treatment: international perspectives. Milano: Springer Milan; 2015. p. 555\u201366."},{"key":"268_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000438988","volume":"22","author":"J Reimer","year":"2016","unstructured":"Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, Mckeganey N, et al. The impact of misuse and diversion of opioid substitution treatment medicines: evidence review and expert consensus. Eur Addict Res. 2016;22:99\u2013106.","journal-title":"Eur Addict Res"},{"key":"268_CR27","first-page":"25","volume":"17","author":"H Alho","year":"2015","unstructured":"Alho H, D\u2019Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, et al. The extent of misuse and diversion of medication for agonist opioid treatment: a review and expert opinions. Heroin Addiction and Related Clinical Problems. 2015;17:25\u201334.","journal-title":"Heroin Addiction and Related Clinical Problems."},{"key":"268_CR28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1360-0443.2010.03014.x","volume":"105","author":"J Bell","year":"2010","unstructured":"Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician\u2019s perspective. Addiction. 2010;105:1531\u20137.","journal-title":"Addiction"},{"key":"268_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugpo.2015.12.024","volume":"29","author":"B Schulte","year":"2016","unstructured":"Schulte B, Schmidt CS, Strada L, Gotzke C, Hiller P, Fischer B, et al. Non-prescribed use of opioid substitution medication: patterns and trends in sub-populations of opioid users in Germany. Int J Drug Policy. 2016;29:57\u201365.","journal-title":"Int J Drug Policy"},{"key":"268_CR30","volume-title":"Statistical Bulletin 2017","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2017","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Statistical Bulletin 2017. Lisbon: EMCDDA; 2017. Available from: \n                    http:\/\/www.emcdda.europa.eu\/data\/stats2017_en"},{"issue":"1","key":"268_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/002204260703700109","volume":"37","author":"K Kalina","year":"2007","unstructured":"Kalina K. Developing the system of drug services in the Czech Republic. J Drug Issues. 2007;37(1):181\u2013204.","journal-title":"J Drug Issues"},{"key":"268_CR32","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu a v\u00fdvoji ve v\u011bcech drog v \u010cesk\u00e9 republice za rok 2001","author":"T Z\u00e1bransk\u00fd","year":"2002","unstructured":"Z\u00e1bransk\u00fd T, Cs\u00e9my L, Gajdo\u0161\u00edkov\u00e1 H, Kor\u010di\u0161ov\u00e1 B, Kuda A, Miovsk\u00fd M, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu a v\u00fdvoji ve v\u011bcech drog v \u010cesk\u00e9 republice za rok 2001. Praha: \u00da\u0159ad vl\u00e1dy \u010cR; 2002."},{"key":"268_CR33","volume-title":"V\u011bstn\u00edk MZ \u010cR \u010d\u00e1stka 3\/2008 - Standard substitu\u010dn\u00ed l\u00e9\u010dby","author":"Ministerstvo zdravotnictv\u00ed \u010cR","year":"2008","unstructured":"Ministerstvo zdravotnictv\u00ed \u010cR. V\u011bstn\u00edk MZ \u010cR \u010d\u00e1stka 3\/2008 - Standard substitu\u010dn\u00ed l\u00e9\u010dby. Praha: Ministerstvo zdravotnictv\u00ed \u010cR; 2008."},{"key":"268_CR34","volume-title":"EPAR summary for the public","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. EPAR summary for the public. Suboxone London: EMA; 2015. Available from: \n                    https:\/\/www.ema.europa.eu\/documents\/overview\/suboxone-epar-summary-public_en.pdf\n                    \n                  ."},{"issue":"4","key":"268_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","volume":"105","author":"SD Comer","year":"2010","unstructured":"Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, et al. Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105(4):709\u201318.","journal-title":"Addiction"},{"issue":"3","key":"268_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0269881118756015","volume":"32","author":"E Kelty","year":"2018","unstructured":"Kelty E, Cumming C, Troeung L, Hulse G. Buprenorphine alone or with naloxone: which is safer? Journal of psychopharmacology (Oxford, England). 2018;32(3):344\u201352.","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"268_CR37","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2015","author":"V Mrav\u010d\u00edk","year":"2016","unstructured":"Mrav\u010d\u00edk V, Chomynov\u00e1 P, Grohmannov\u00e1 K, Jan\u00edkov\u00e1 B, Tion Le\u0161tinov\u00e1 Z, Rous Z, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2015. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2016."},{"key":"268_CR38","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2014","author":"V Mrav\u010d\u00edk","year":"2015","unstructured":"Mrav\u010d\u00edk V, Chomynov\u00e1 P, Grohmannov\u00e1 K, Jan\u00edkov\u00e1 B, Grolmusov\u00e1 L, Tion Le\u0161tinov\u00e1 Z, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2014. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2015."},{"key":"268_CR39","volume-title":"Zneu\u017e\u00edv\u00e1n\u00ed psychoaktivn\u00edch l\u00e9k\u016f v \u010cesk\u00e9 republice. Idnetifikace zdroj\u016f dat","author":"B Nechansk\u00e1","year":"2012","unstructured":"Nechansk\u00e1 B, Mrav\u010d\u00edk V, Popov P. Zneu\u017e\u00edv\u00e1n\u00ed psychoaktivn\u00edch l\u00e9k\u016f v \u010cesk\u00e9 republice. Idnetifikace zdroj\u016f dat. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2012."},{"key":"268_CR40","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2016","author":"V Mrav\u010d\u00edk","year":"2017","unstructured":"Mrav\u010d\u00edk V, Chomynov\u00e1 P, Grohmannov\u00e1 K, Jan\u00edkov\u00e1 B, Tion Le\u0161tinov\u00e1 Z, Rous Z, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2016. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2017."},{"key":"268_CR41","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va: incidence, prevalence, zdravotn\u00ed dopady a trendy l\u00e9\u010den\u00fdch u\u017eivatel\u016f drog v \u010cesk\u00e9 republice v roce 2014","author":"A F\u00fcleov\u00e1","year":"2015","unstructured":"F\u00fcleov\u00e1 A, Z\u00f3nov\u00e1 J, Petr\u00e1\u0161ov\u00e1 B. V\u00fdro\u010dn\u00ed zpr\u00e1va: incidence, prevalence, zdravotn\u00ed dopady a trendy l\u00e9\u010den\u00fdch u\u017eivatel\u016f drog v \u010cesk\u00e9 republice v roce 2014. Praha: Hygienick\u00e1 stanice hl. m. Prahy; 2015."},{"issue":"1","key":"268_CR42","first-page":"13","volume":"7","author":"V Mrav\u010d\u00edk","year":"2007","unstructured":"Mrav\u010d\u00edk V, Orl\u00edkov\u00e1 B. P\u0159ekryv klient\u016f mezi jednotliv\u00fdmi n\u00edzkoprahov\u00fdmi programy a zneu\u017e\u00edv\u00e1n\u00ed buprenorfinu v Praze. Adiktologie. 2007;7(1):13\u201320.","journal-title":"Adiktologie."},{"issue":"65","key":"268_CR43","first-page":"56","volume":"1","author":"V Mrav\u010d\u00edk","year":"2016","unstructured":"Mrav\u010d\u00edk V, Flori\u00e1n Z, Ne\u010das V, \u0160tolfa J. Infek\u010dn\u00ed a dal\u0161\u00ed somatick\u00e1 komorbidita probl\u00e9mov\u00fdch u\u017eivatel\u016f drog - v\u00fdsledky pr\u016f\u0159ezov\u00e9 studie s l\u00e9ka\u0159sk\u00fdm vy\u0161et\u0159en\u00edm. Epidemiol Mikrobiol Imunol. 2016;1(65):56\u201362.","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"268_CR44","unstructured":"Malinovsk\u00e1 J, Mrav\u010d\u00edk V. Probl\u00e9mov\u00e9 u\u017e\u00edv\u00e1n\u00ed opioid\u016f mezi klienty n\u00edzkoprahov\u00fdch kontaktn\u00edch center v Praze: dotazn\u00edkov\u00e9 \u0161et\u0159en\u00ed. Adiktologie Adiktologie 2017;17(4):262\u2013271."},{"issue":"4","key":"268_CR45","first-page":"282","volume":"17","author":"J Malinovsk\u00e1","year":"2017","unstructured":"Malinovsk\u00e1 J, Mrav\u010d\u00edk V. V\u00fdvoj probl\u00e9mov\u00e9ho u\u017e\u00edv\u00e1n\u00ed opioid\u016f na \u00fazem\u00ed \u010cesk\u00e9 republiky: liter\u00e1rn\u00ed p\u0159ehled. Adiktologie. 2017;17(4):282\u201391.","journal-title":"Adiktologie."},{"key":"268_CR46","volume-title":"Spot\u0159eba injek\u010dn\u00edho materi\u00e1lu klienty pra\u017esk\u00fdch harm reduction slu\u017eeb v z\u00e1vislosti na vzorc\u00edch u\u017e\u00edv\u00e1n\u00ed (Consumption of material for injection clients of Prague harm reduction services depending on use patterns) [Mgr.]","author":"H \u0160v\u016fgerov\u00e1","year":"2015","unstructured":"\u0160v\u016fgerov\u00e1 H. Spot\u0159eba injek\u010dn\u00edho materi\u00e1lu klienty pra\u017esk\u00fdch harm reduction slu\u017eeb v z\u00e1vislosti na vzorc\u00edch u\u017e\u00edv\u00e1n\u00ed (Consumption of material for injection clients of Prague harm reduction services depending on use patterns) [Mgr.]. Praha: Univerzita Karlova v Praze, 1. l\u00e9ka\u0159sk\u00e1 fakulta, obor adiktologie (MADI); 2015."},{"key":"268_CR47","unstructured":"V\u011btrovec M. U\u017e\u00edv\u00e1n\u00ed buprenorfinu na pra\u017esk\u00e9 drogov\u00e9 sc\u00e9n\u011b (Buprenorphine use in the Prague drug scene). Conference \"Perspektivy Harm Reduction v Praze\"; Prague: SANANIM; 2003."},{"key":"268_CR48","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2011","author":"V Mrav\u010d\u00edk","year":"2012","unstructured":"Mrav\u010d\u00edk V, Grohmannov\u00e1 K, Chomynov\u00e1 P, Ne\u010das V, Grolmusov\u00e1 L, Ki\u0161\u0161ov\u00e1 L, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2011. Praha: \u00da\u0159ad vl\u00e1dy \u010cR; 2012."},{"key":"268_CR49","unstructured":"Mrav\u010d\u00edk V, Chomynov\u00e1 P, Grohmannov\u00e1 K, Ne\u010das V, Grolmusov\u00e1 L, Ki\u0161\u0161ov\u00e1 L, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2013. Mrav\u010d\u00edk V, editor. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky. ; 2014."},{"issue":"3 - supplementu","key":"268_CR50","first-page":"410","volume":"4","author":"M \u0158ezn\u00ed\u010dkov\u00e1","year":"2004","unstructured":"\u0158ezn\u00ed\u010dkov\u00e1 M, Nedv\u011bd T. Zku\u0161enosti ter\u00e9nn\u00edch pracovn\u00edk\u016f s u\u017eivateli Subutexu na otev\u0159en\u00e9 drogov\u00e9 sc\u00e9n\u011b. Adiktologie. 2004;4(3 - supplementum):410\u20131.","journal-title":"Adiktologie"},{"key":"268_CR51","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jpainsymman.2014.02.013","volume":"48","author":"MJM Vranken","year":"2014","unstructured":"Vranken MJM, Mantel-Teeuwisse AK, J\u00fcnger S, Radbruch L, Lisman J, Scholten W, et al. Legal barriers in accessing opioid medicines: results of the ATOME quick scan of national legislation of eastern European countries. J Pain Symptom Manag. 2014;48:1135\u201344.","journal-title":"J Pain Symptom Manag"},{"key":"268_CR52","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2003","author":"V Mrav\u010d\u00edk","year":"2004","unstructured":"Mrav\u010d\u00edk V, Kor\u010di\u0161ov\u00e1 B, Lej\u010dkov\u00e1 P, Miovsk\u00e1 L, \u0160krdlantov\u00e1 E, Petro\u0161 O, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o stavu ve v\u011bcech drog v \u010cesk\u00e9 republice v roce 2003. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2004."},{"key":"268_CR53","volume-title":"V\u00fdro\u010dn\u00ed zpr\u00e1va o hazardn\u00edm hran\u00ed v \u010cesk\u00e9 republice v roce 2014","author":"V Mrav\u010d\u00edk","year":"2015","unstructured":"Mrav\u010d\u00edk V, Rous Z, Tion Le\u0161tinov\u00e1 Z, Drbohlavov\u00e1 B, Chomynov\u00e1 P, Grohmannov\u00e1 K, et al. V\u00fdro\u010dn\u00ed zpr\u00e1va o hazardn\u00edm hran\u00ed v \u010cesk\u00e9 republice v roce 2014. Praha: \u00da\u0159ad vl\u00e1dy \u010cesk\u00e9 republiky; 2015."},{"key":"268_CR54","first-page":"2009","volume-title":"Treating drug misuse problems: evidence of effectiveness","author":"M Gossop","year":"2006","unstructured":"Gossop M. Treating drug misuse problems: evidence of effectiveness. London: National treatment Agency for Substance Misuse; 2006. p. 2009."},{"key":"268_CR55","volume-title":"Review of the efficacy of drug treatment interventions in Europe: European Commission and Centre for interdisciplinary addiction research (ZIS) of the Hamburg University","author":"B Schulte","year":"2008","unstructured":"Schulte B, Thane K, Rehm J, Uchtenhagen A, St\u00f6ver H, Degkwitz P, et al. Review of the efficacy of drug treatment interventions in Europe: European Commission and Centre for interdisciplinary addiction research (ZIS) of the Hamburg University; 2008."},{"issue":"4","key":"268_CR56","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10550880903183042","volume":"28","author":"A Fareed","year":"2009","unstructured":"Fareed A, Casarella J, Roberts M, Sleboda M, Amar R, Vayalapalli S, et al. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis. 2009;28(4):399\u2013405.","journal-title":"J Addict Dis"},{"issue":"6","key":"268_CR57","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1521-0391.2010.00086.x","volume":"19","author":"I Maremmani","year":"2010","unstructured":"Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict. 2010;19(6):557\u201368.","journal-title":"Am J Addict"},{"issue":"2","key":"268_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/00952990.2011.643988","volume":"38","author":"A Fareed","year":"2012","unstructured":"Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse. 2012;38(2):155\u201360.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"268_CR59","unstructured":"\u010cesk\u00fd statistick\u00fd \u00fa\u0159ad. Pr\u016fm\u011brn\u00e1 hrub\u00e1 m\u011bs\u00ed\u010dn\u00ed mzda zam\u011bstnanc\u016f v n\u00e1rodn\u00edm hospod\u00e1\u0159stv\u00ed podle ekonomick\u00e9 \u010dinnosti (sekce CZ-NACE) - z ro\u010dn\u00edho zji\u0161\u0165ov\u00e1n\u00ed Prague: \u010cesk\u00fd statistick\u00fd \u00fa\u0159ad; 2018 [cited 2019 6 Oct]. Available from: \n                    https:\/\/www.czso.cz\/documents\/10180\/60664312\/1100251807.pdf\/957401d8-cfe1-4f37-b748-80fe29f7d536?version\n                    \n                  ."},{"key":"268_CR60","unstructured":"Bi\u010d\u00e1kov\u00e1 O. Zv\u00fd\u0161en\u00ed minim\u00e1ln\u00ed mzdy od 1. ledna 2016. N\u00e1rodn\u00ed poji\u0161t\u011bn\u00ed. 2015(11). Available from: \n                    https:\/\/www.cssz.cz\/cz\/casopis-narodni-pojisteni\/archiv-vydanych-cisel\/2015-11-03-zvyseni-minimalni-mzdy-od-1-ledna-2016.htm\n                    \n                  ."},{"key":"268_CR61","unstructured":"Gluzov\u00e1 J. Vzorce u\u017e\u00edv\u00e1n\u00ed buprenorfinu u klint\u016f Ter\u00e9nn\u00edho programu SANANIM (Patterns of buprenorphine use among clients of Outreach Programme SANANIM) [Bc.]. Praha: Univerzita Karlova v Praze, 1. l\u00e9ka\u0159sk\u00e1 fakulta, obor adiktologie (BADI); 2014."},{"key":"268_CR62","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.drugalcdep.2016.03.017","volume":"162","author":"E Launonen","year":"2016","unstructured":"Launonen E, Wallace I, Kotovirta E, Alho H, Simojoki K. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. Drug Alcohol Depend. 2016;162:227\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"268_CR63","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/ADM.0b013e318262a97a","volume":"6","author":"HK Knudsen","year":"2012","unstructured":"Knudsen HK, Roman PM. Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med. 2012;6(4):280\u20136.","journal-title":"J Addict Med"},{"issue":"8","key":"268_CR64","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","volume":"32","author":"B Nosyk","year":"2013","unstructured":"Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health affairs (Project Hope). 2013;32(8):1462\u20139.","journal-title":"Health affairs (Project Hope)"},{"key":"268_CR65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","volume":"36","author":"A Kolodny","year":"2015","unstructured":"Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559\u201374.","journal-title":"Annu Rev Public Health"},{"key":"268_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1874473711104010028","volume":"4","author":"MA Yokell","year":"2011","unstructured":"Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review. Current Drug Abuse Review. 2011;4:28\u201341.","journal-title":"Current Drug Abuse Review"},{"key":"268_CR67","unstructured":"Pompidou Group Opioid Agonist Treatment. Guiding principles for legislation and regulations. Expert group on the regulatory framework for the treatment of opioid dependence syndrome and the prescription of opioid agonist medicines. Strasbourg: Council of Europe; 2017."},{"key":"268_CR68","first-page":"33","volume":"10","author":"K Simojoki","year":"2008","unstructured":"Simojoki K, Alho H. Finnish experience with buprenorphine-naloxone combination (Suboxone\u00ae): survey evaluations with intravenous drug users. Heroin Addiction and Related Clinical Problems. 2008;10:33\u20136.","journal-title":"Heroin Addiction and Related Clinical Problems"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0268-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-018-0268-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0268-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T19:33:32Z","timestamp":1575401612000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-018-0268-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1186\/s12954-018-0268-0","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"30 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VM and PP received a fee for a presentation within a session sponsored by Indivior Cesko s.r.o. at national conference. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"60"}}